The FDA approval of Pixclara is a major commercial catalyst that should drive near-term revenue growth and de-risk the stock. Traders should watch for initial U.S. sales data, reimbursement decisions, and updates on the Phase 3 brain metastases expansion study.
TLX drugs
TLX drug pipeline →- ◆ ITM-11 4/10 Phase 3 (completed)
- ● TLX591-Tx 4/10 Phase 3
- ● Zircaix 4/10 Phase 3 (ZIRCON) completed; BLA under FDA review
- ▲ Gozellix 3/10 Approved (FDA, March 21, 2025 — NDA 219592, 505(b)(2))
- ● TLX101-Tx 3/10 Phase 3 (pivotal, just initiated); Phase 1 safety stage complete
- All TLX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 15 $12.83entry
- T+1 · 2mo ago −7.79%α −7.35% · $11.83
- T+5 · 8w ago −6.86%α −8.99% · $11.95
- T+20 · 5w ago −14.89%α −17.61% · $10.92
- T+44 · todayOpen
- T+60 · in 22d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Telix Pharmaceuticals announced FDA approval of Pixclara (floretyrosine F 18), the first FDA-approved FET-PET imaging drug for glioma (brain cancer). This is a transformative regulatory milestone that opens a new commercial product line in a large, underserved U.S. market (~24,000 new glioma cases/year) and reinforces Telix's leadership in theranostics. The approval is a clear, material positive catalyst for the stock.
Key Facts
- FDA approved Pixclara (floretyrosine F 18) for PET imaging to differentiate recurrent/progressive glioma from treatment-related change in adults and pediatric patients 1 month+
- Pixclara is the first and only FDA-approved radiopharmaceutical imaging drug for glioma (brain cancer)
- Approximately 24,000 new glioma cases are diagnosed annually in the U.S., representing a significant addressable market
- FET-PET imaging is recommended in international clinical practice guidelines, including NCCN Guidelines
- Pixclara expands Telix's commercial precision diagnostics portfolio alongside Illuccix and Gozellix
- Pixclara (TLX101-Px) is also in a Phase 3 registrational study for potential indication expansion in brain metastases
Financial Impact
Opens a new commercial revenue stream in a ~24,000-patient/year U.S. market for the first FDA-approved glioma PET imaging agent; no specific revenue guidance or pricing provided in the filing
Risk Factors
- Commercial adoption and reimbursement may be slower than expected
- Competition from other imaging modalities or future FDA-approved products
- Pixclara is a diagnostic agent; revenue contribution may be modest relative to therapeutic pipeline
- Phase 3 brain metastases study may not succeed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-061892 |
| Document: pixclaraapprovalvfinal.htm | 0001628280-26-061892 |
| Document: 0001628280-26-061892-index-headers.html | 0001628280-26-061892 |
| Document: 0001628280-26-061892-index.html | 0001628280-26-061892 |
| Document: 0001628280-26-061892.txt | 0001628280-26-061892 |
Track record
27 reports on TLX
10 of 20 bullish or bearish reports moved the stock their way by T+1. Best: +29.26% at T+20 after the Jun 1, 2026 report. 19 of 20 went positive at some point.
Filters
- Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
- Oct 20, 202627d ago 6-K Neutral 4/10 No price data
- Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
- Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
- Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 14, 20269w ago 6-K Bullish 8/10 Viewing Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
- Sep 14, 20269w ago Press Release Bullish 8/10 Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
- Sep 1, 202610w ago 6-K Bullish 7/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
- Sep 1, 202610w ago Press Release Bullish 6/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers